基石药业:25 年港股医药或迎反弹 买入

和讯网
08 Feb

【2 月 8 日,招商证券国际发布年度全球医药、医疗行业报告】招商证券国际称,看好基石药业在临床试验上的高效运营及在下一代肿瘤免疫领域的前瞻性布局,未来 ROR1 产品有望提升公司估值,维持其“买入”评级,目标价 7.3 港元,并将其列为中小生物技术企业核心推荐。该行建议超配港股医药行业,因港股医药股处于近 4 年底部位置,2025 年随业绩明朗和监管信息趋正,港股医药将迎反弹机会。此外,国家医保...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10